SCHEDULE 13G/A: Fairmount Funds Management Discloses 9.9% Stake in Inhibikase Therapeutics

Fairmount Funds Management LLC and its affiliates have disclosed a 9.9% beneficial ownership stake in Inhibikase Therapeutics, Inc., comprising common stock and exercisable pre-funded warrants, as of December 31, 2024.

Summary

• Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Peter Harwin, and Tomas Kiselak collectively reported beneficial ownership of 7,018,575 shares of Inhibikase Therapeutics, Inc. common stock.
• This represents 9.9% of the Issuer's common stock outstanding as of December 31, 2024, based on 69,362,439 shares outstanding.
• The reported ownership includes 6,125,000 directly held common shares by Fairmount Healthcare Fund II L.P.
• It also includes 893,575 shares acquirable through the exercise of pre-funded warrants, which are part of a larger pool of 4,460,000 pre-funded warrants.
• A beneficial ownership limitation prevents the exercise of pre-funded warrants if it would result in ownership exceeding 9.99% of the outstanding common stock.
• Fairmount Healthcare Fund II L.P. also holds 5,290,872 Series A-1 Warrants (exercise price $1.37) and 9,729,523 Series B-1 Warrants (exercise price $1.49), but beneficial ownership of these is disclaimed as they are not exercisable within 60 days.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. A significant institutional stake can be viewed positively, but the filing itself is purely factual and regulatory. The beneficial ownership limitation and contingent warrant exercises add complexity but are not inherently negative.

Risks

• The exercise of Pre-Funded Warrants is subject to a Beneficial Ownership Limitation, preventing ownership from exceeding 9.99% of outstanding common stock.
• The Series A-1 and B-1 Warrants are not currently exercisable within 60 days, and their exercise is contingent on specific future events, including SEC review of a registration statement, a Phase 2b safety readout for IkT-001Pro with respect to pulmonary arterial hypertension, and stockholder approval to increase authorized shares.

Future Outlook

The exercise of Series A-1 and B-1 Warrants is contingent upon future events, including the SEC's review status of a registration statement, the public announcement of Phase 2b 12-week safety readout for IkT-001Pro concerning pulmonary arterial hypertension, and stockholder approval to increase the number of authorized shares of common stock.

Industry Context

This filing primarily concerns institutional ownership disclosure and does not provide specific insights into broader industry trends or competitive landscape for Inhibikase Therapeutics, Inc.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake may influence market perception and potentially share price. The existence of warrants could lead to future dilution if exercised.

Next Steps

• SEC review of the Warrant Initial Registration Statement.
• Issuer's public announcement of Phase 2b 12-week safety readout for IkT-001Pro with respect to pulmonary arterial hypertension.
• Issuer obtaining stockholder approval for an amendment to increase authorized shares of Common Stock.
• Issuer filing an amendment to its Certificate of Incorporation with the Secretary of State of Delaware.
• Potential exercise of Series A-1 and B-1 Warrants upon meeting specified conditions.

Key Dates

Keywords

Inhibikase Therapeutics, Fairmount Funds Management, Fairmount Healthcare Fund II, Schedule 13G, Beneficial Ownership, Common Stock, Pre-Funded Warrants, Series A-1 Warrants, Series B-1 Warrants, SEC Filing, Institutional Ownership, Biotechnology, Pharmaceuticals, IkT-001Pro, Pulmonary Arterial Hypertension